Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 for colorectal brain metastases imaging
NCT04755920Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoint: Feasibility of SGM-101 for intraoperative imaging. Started Jan 2024; status: recruiting.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04755920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755920.